An 'all-inclusive' 96-well cytochrome P450 induction method: Measuring enzyme: Activity, mrna levels, protein levels, and cytotoxicity from one well using: Cryopreserved human hepatocytes

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 3, 2012, Pages 270-275

  Halladay, Jason S ^a   Wong, Susan ^a   Cyrus Khojasteh, S ^a   Grepper, Susan ^b  

^a GENENTECH INC   (United States)

^b Life Technologies   (United States)

Author keywords

Cytochrome P450; Drug drug interactions; Induction; mRNA; Primary human hepatocytes; Protein

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; LACTATE DEHYDROGENASE; MESSENGER RNA; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; RITONAVIR; STAUROSPORINE;

ARTICLE; CELL CULTURE; CELL VIABILITY; CRYOPRESERVATION; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL; MALE; PROTEIN EXPRESSION;

EID: 84870669368     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.07.004     Document Type: Article

References (20)

1. Almond, L. M., Yang, J., et al. (2009). Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Current Drug Metabolism, 10(4), 420-432.
2. Bjornsson, T. D., Callaghan, J. T., et al. (2003). The conduct of in vitro and in vivo drug- drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metabolism and Disposition, 31(7), 815-832.
3. Decker, T., & Lohmann-Matthes, M. L. (1988). A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. Journal of Immunological Methods, 115(1), 61-69.
4. Dixit, V., Hariparsad, N., et al. (2007). Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: Implications for predicting clinical drug interactions. Drug Metabolism and Disposition, 35(10), 1853-1859.
5. Halladay, J. S., Wong, S., et al. (2007). Metabolic stability screen for drug discovery using cassette analysis and column switching. Drug Metabolism Letters, 1(1), 67-72.
6. Kashuba, A. D. (2005). Drug-drug interactions and the pharmacotherapy of HIV infection. Topics in HIV Medicine, 13(2), 64-69.
7. LeCluyse, E. L. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. European Journal of Pharmaceutical Sciences, 13(4), 343-368.
8. Lee, W. M. (2003). Drug-induced hepatotoxicity. The New England Journal of Medicine, 349(5), 474-485.
9. Madan, A., Graham, R. A., et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition, 31(4), 421-431.
10. Maglich, J. M., Stoltz, C. M., et al. (2002). Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular Pharmacology, 62(3), 638-646.
11. McNicholl, I. R. (2004). Drug interactions among the antiretrovirals. Current Infectious Disease Reports, 6(2), 159-162.
12. Nakata, K., Tanaka, Y., et al. (2006). Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metabolism and Pharmacokinetics, 21(6), 437-457.
13. O'Brien, J., Wilson, I., et al. (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European Journal of Biochemistry, 267(17), 5421-5426.
14. Rae, J. M., Johnson, M. D., et al. (2001). Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. Journal of Pharmacology and Experimental Therapeutics, 299(3), 849-857.
15. Roymans, D., Van Looveren, C., et al. (2004). Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochemical Pharmacology, 67(3), 427-437.
16. Smith, D. A. (2000). Induction and drug development. European Journal of Pharmaceutical Sciences, 11(3), 185-189.
17. Tirona, R. G., & Kim, R. B. (2005). Nuclear receptors and drug disposition gene regulation. Journal of Pharmaceutical Sciences, 94(6), 1169-1186.
18. Tucker, G. T., Houston, J. B., et al. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. British Journal of Clinical Pharmacology, 52(1), 107-117.
19. Wienkers, L. C., & Heath, T. G. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews. Drug Discovery, 4(10), 825-833.
20. Wong, S., Carle, J., et al. (2007). New methodology for measuring mRNA levels along with monitoring CYP activity in induction studies using human plateable cryopreserved hepatocytes. Drug Metabolism Reviews, 39(s1), 1-388.